As the largest Gynecologic Site Group in Canada, our group offers cutting-edge, novel clinical programs that support women at risk for, or who have been diagnosed with, cervical, tubal, ovarian, uterine, vaginal, vulvar or rare gynecological cancers.
From screening, diagnosis and treatment planning and delivery through to survivorship, our group continuously strives to ensure that we are setting the standard for best practices in cancer prevention and patient-centred care.
In addition to our clinical programs and cutting-edge technology and surgical practices, our internationally recognized drug development program offers a range of Phase I, II and III clinical trials. See also: Clinical Trials at Princess Margaret »
Our group provides the most recent standard of care with an emphasis on innovative treatment.